Skip to main content
SpringerLink
Log in

Understanding the Agent, Part II: Adverse Effects

  • Chapter
  • First Online:
Opioid Dependence

  • 1245 Accesses

Abstract

The decision to prescribe or use opioids—whether short term or long term—must be grounded in a full understanding of the drug class and the current evidence for both benefit and risk. Opioids remain some of the most dangerous drugs in the therapeutic armamentarium and confer a high degree of morbidity and mortality. Adverse effects of the class affect virtually every physiologic system, including neuropsychiatric, cardiovascular, respiratory, immunologic, endocrine, gastroenterologic, urinary, and dermatologic. Tolerance to the analgesic (and euphoric) effects of opioids is almost universal with prolonged use, and tolerance to some but not all of the adverse effects is common as well. Reduced efficacy with chronic use often leads to dose escalation which heightens the risks. Opioid-induced hyperalgesia is a commonly seen phenomenon whereby chronic use actually increases pain sensitivity; the only rational treatment decision in this situation is to reduce or eliminate opioid therapy. Last but certainly not the least, the risks of physical and psychological dependence and addiction and the grim consequences of these conditions are far more prevalent than was publicized 20 years ago.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 129.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Pimentel L, Mayo D. Chronic methadone therapy complicated by torsades de pointes: a case report. J Emerg Med. 2008;34:287–90.

    Article  PubMed  Google Scholar 

  2. Fishman SM. Responsible opioid prescribing–a clinician’s guide. 2nd ed. Washington, D.C.: Waterford Life Sciences; 2014.

    Google Scholar 

  3. Chowdhury MM, Board R. Morphine-induced hallucinations - resolution with switching to oxycodone: a case report and review of the literature. Cases J. 2009;2:9391.

    Article  PubMed  PubMed Central  Google Scholar 

  4. White KL, Roth BL. Psychotomimetic effects of kappa opioid receptor agonists. Biol Psychiatry. 2012;72:797–8.

    Article  CAS  PubMed  Google Scholar 

  5. Dogra S, Yadav PN. Biased agonism at kappa opioid receptors: implication in pain and mood disorders. Eur J Pharmacol. 2015;763(Pt B):184–90.

    Article  CAS  PubMed  Google Scholar 

  6. Schmauss C, Yassouridis A, Emrich HM. Antipsychotic effect of buprenorphine in schizophrenia. Am J Psychiatry. 1987;144:1340–2.

    Article  CAS  PubMed  Google Scholar 

  7. Scherrer JF, Salas J, Copeland LA, Stock EM, Ahmedani BK, Sullivan MD, et al. Prescription opioid duration, dose, and increased risk of depression in 3 large patient populations. Ann Fam Med. 2016;14:54–62.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Scherrer JF, Salas J, Lustman PJ, Burge S, Schneider FD, Residency Research Network of Texas (RRNeT) Investigators. Change in opioid dose and change in depression in a longitudinal primary care patient cohort. Pain. 2015;156:348–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Lutz PE, Kieffer BL. Opioid receptors: distinct roles in mood disorders. Trends Neurosci. 2013;36:195–206.

    Article  CAS  PubMed  Google Scholar 

  10. Bodkin JA, Zornberg GL, Lukas SE. Buprenorphine treatment of refractory depression. J Clin Psychopharmacol. 1995;15:49–57.

    Article  CAS  PubMed  Google Scholar 

  11. Machado-Vieira R, Zarate CA Jr. Proof of concept trials in bipolar disorder and major depressive disorder: a translational perspective in the search for improved treatments. Depress Anxiety. 2011;28:267–81.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Peppin JF, Raffa RB. Delta opioid agonists: a concise update on potential therapeutic applications. J Clin Pharm Ther. 2015;40(2):155–66.

    Article  CAS  PubMed  Google Scholar 

  13. Gardner E. Introduction: addiction and brain reward and anti-reward pathways. Adv Psychosom Med. 2011;30:22–60.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Chartoff EH, Connery HS. It’s MORe exciting than mu: crosstalk between mu opioid receptors and glutamatergic transmission in the mesolimbic dopamine system. Front Pharmacol. 2014;5:116.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Koob GF. The dark side of emotion: the addiction perspective. Eur J Pharmacol. 2015;753:73–87.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Washington, D.C.: American Psychiatric Association; 2013.

    Book  Google Scholar 

  17. National Institute on Drug Abuse. Misuse of prescription drugs. 2017. https://www.drugabuse.gov/publications/research-reports/misuseprescription-drugs/summary. Accessed 18 Aug 2017

  18. National Institute on Drug Abuse. NIDA research report series–prescription drug abuse. 2014. Available from: https://www.drugabuse.gov/publications/research-reports/prescription-drugs/what-prescription-drug-abuse.

    Google Scholar 

  19. UNODC, World drug report 2012. http://www.unodc.org/unodc/en/data-and-analysis/WDR-2012.html.

    Google Scholar 

  20. Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. Behavioral health trends in the United States: results from the 2014 national survey on drug use and health. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2015.

    Google Scholar 

  21. Edlund MJ, Martin BC, Fan MY, Devries A, Braden JB, Sullivan MD. Risks for opioid abuse and dependence among recipients of chronic opioid therapy: results from the TROUP study. Drug Alcohol Depend. 2010;112:90–8.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Vowles KE, McEntee ML, Julnes PS, Frohe T, Ney JP, van der Goes DN. Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis. Pain. 2015;156:569–76.

    Article  PubMed  Google Scholar 

  23. Sehgal N, Manchikanti L, Smith HS. Prescription opioid abuse in chronic pain: a review of opioid abuse predictors and strategies to curb opioid abuse. Pain Physician. 2012;15:ES67–92.

    PubMed  Google Scholar 

  24. Palmer R, Carrel D, Cronkite D, Saunders K, Gross D, Masters E, et al. The prevalence and characteristics of patients with indicators of opioid abuse within an integrated group practice. J Pain. 2014;15(Supplement):S25.

    Article  Google Scholar 

  25. Fishbain DA, Cole B, Lewis J, Rosomoff HL, Rosomoff RS. What percentage of chronic nonmalignant pain patients exposed to chronic opioid analgesic therapy develop abuse/addiction and/or aberrant drug-related behaviors? A structured evidence-based review. Pain Med. 2008;9:444–59.

    Article  PubMed  Google Scholar 

  26. Fukuda K. Opioid analgesics. In: Miller R, editor. Miller’s anesthesia. Philadelphia: Saunders; 2014. p. 864–914.

    Google Scholar 

  27. Smith HS, McCleane G, Thompson G. Optimizing pharmacologic outcomes: assessing and managing opioid side effects. In: Smith HS, editor. Opioid therapy in the 21st century. Oxford: Oxford University Press; 2013. p. 79–103.

    Google Scholar 

  28. Li Y, van den Pol AN. Mu-opioid receptor-mediated depression of the hypothalamic hypocretin/orexin arousal system. J Neurosci. 2008;28:2814–9.

    Article  CAS  PubMed  Google Scholar 

  29. Osman NI, Baghdoyan HA, Lydic R. Morphine inhibits acetylcholine release in rat prefrontal cortex when delivered systemically or by microdialysis to basal forebrain. Anesthesiology. 2005;103:779–87.

    Article  CAS  PubMed  Google Scholar 

  30. Bagetta G, De Sarro GB, Sakurada S. Different profile of electrocortical power spectrum changes after micro-infusion into the locus coeruleus of selective agonists at various opioid receptor subtypes in rats. Br J Pharmacol. 1990;101:655–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Van Bockstaele EJ, Valentino RJ. Neuropeptide regulation of the locus coeruleus and opiate-induced plasticity of stress responses. Adv Pharmacol. 2013;68:405–20.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Cheatle MD, Webster LR. Opioid therapy and sleep disorders: risks and mitigation strategies. Pain Med. 2015;16:S22–6.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Dhingra L, Ahmed E, Shin J, Scharaga E, Magun M. Cognitive effects and sedation. Pain Med. 2015;16:S37–43.

    Article  PubMed  Google Scholar 

  34. McNicol E, Horowicz-Mehler N, Fisk RA. Management of opioid side effects in cancer-related and chronic noncancer pain: a systematic review. J Pain. 2003;4:231–56.

    Article  PubMed  Google Scholar 

  35. Yaksh TL, Wallace MS. Opioids, analgesia, and pain management. In: Brunton L, editor. Goodman and Gilman’s pharmacologic basis of therapeutics. New York: McGraw-Hill; 2011. p. 481–525.

    Google Scholar 

  36. Lee MD, Silverman S, Hansen H, Patel VB, Manchikanti L. A comprehensive review of opioid-induced hyperalgesia. Pain Physician. 2011;14:145–61.

    PubMed  Google Scholar 

  37. Angst MS, Clark JD. Opioid-induced hyperalgesia: a qualitative systematic review. Anesthesiology. 2006;104:570–87.

    Article  CAS  PubMed  Google Scholar 

  38. Celerier E, Laulin JP, Corcuff JB, Le Moal M, Simonnet G. Progressive enhancement of delayed hyperalgesia induced by repeated heroin administration: a sensitization process. J Neurosci. 2001;21:4074–80.

    CAS  PubMed  Google Scholar 

  39. Chen L, Mao J. Optimizing pharmacologic outcomes: opioid-induced hyperalgesia. In: Smith HS, editor. Opioid therapy in the 21st century. Oxford: Oxford University Press; 2013. p. 105–19.

    Google Scholar 

  40. Apkarian AV, Sosa Y, Sonty S, Levy RM, Harden RN, Parrish TB, et al. Chronic back pain is associated with decreased prefrontal and thalamic gray matter density. J Neurosci. 2004;24:10410–5.

    Article  CAS  PubMed  Google Scholar 

  41. Siddall PJ, Stanwell P, Woodhouse A, Somorjai RL, Dolenko B, Nikulin A, et al. Magnetic resonance spectroscopy detects biochemical changes in the brain associated with chronic low back pain: a preliminary report. Anesth Analg. 2006;102:1164–8.

    Article  PubMed  Google Scholar 

  42. Ivo R, Nicklas A, Dargel J. Brain structural and psychometric alterations in chronic low back pain. Eur Spine J. 2013;22:1958–64.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Zhuo M. Long-term potentiation in the anterior cingulate cortex and chronic pain. Phil Trans Royal Soc B. 2014;369:20130146.

    Article  Google Scholar 

  44. Price TJ, Inyang KE. Commonalities between pain and memory mechanisms and their meaning for understanding chronic pain. Prog Mol Biol Transl Sci. 2015;131:409–34.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Doan L, Manders T, Wang J. Neuroplasticity underlying the comorbidity of pain and depression. Neural Plast. 2015;2015:504691.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Beltrán-Campos V, Silva-Vera M, García-Campos ML, Diaz-Cintra S. Effects of morphine on brain plasticity. Neurologia. 2015;30:176–80.

    Article  PubMed  Google Scholar 

  47. Kandasamy R, Price TJ. The pharmacology of nociceptor priming. Handb Exp Pharmacol. 2015;227:15–37.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Sahbaie P, Liang DY, Shi WY. Epigenetic regulation of spinal cord gene expression contributes to enhanced postoperative pain and analgesic tolerance subsequent to continuous opioid exposure. Mol Pain. 2016;12:1–11.

    Article  CAS  Google Scholar 

  49. Mao J, Mayer DJ. Spinal cord neuroplasticity following repeated opioid exposure and its relation to pathological pain. Ann N Y Acad Sci. 2001;933:175–84.

    Article  CAS  PubMed  Google Scholar 

  50. Dahan A, Aarts L, Smith TW. Incidence, reversal, and prevention of opioid-induced respiratory depression. Anesthesiology. 2010;112:226–38.

    Article  PubMed  Google Scholar 

  51. Cashman JN, Dolin SJ. Respiratory and haemodynamic effects of acute postoperative pain management: evidence from published data. Br J Anaesth. 2004;93:212–23.

    Article  CAS  PubMed  Google Scholar 

  52. West JB. Respiratory physiology: the essentials. 9th ed. Baltimore, MD: Lippincott Williams and Wilkins; 2012.

    Google Scholar 

  53. Dahan A, Sarton E, Teppema L, Olievier C, Nieuwenhuijs D, Matthes HW, et al. Anesthetic potency and influence of morphine and sevoflurane on respiration in mu-opioid receptor knockout mice. Anesthesiology. 2001;94(5):824–32.

    Article  CAS  PubMed  Google Scholar 

  54. Pattinson KTS. Opioids and the control of respiration. Br J Anesth. 2008;100:747–58.

    Article  CAS  Google Scholar 

  55. Jann M, Kennedy WK, Lopez G. Benzodiazepines: a major component in unintentional prescription drug overdoses with opioid analgesics. J Pharm Pract. 2014;27:5–16.

    Article  PubMed  Google Scholar 

  56. Jones CM, Paulozzi LJ, Mack KA. Alcohol involvement in opioid pain reliever and benzodiazepine drug abuse–related emergency department visits and drug-related deaths — United States, 2010. MMWR. 2014;63(40):881–5.

    PubMed  Google Scholar 

  57. Walker JM, Farney RJ, Rhondeau SM, Boyle KM, Valentine K, Cloward TV, et al. Chronic opioid use is a risk factor for the development of central sleep apnea and ataxic breathing. J Clin Sleep Med. 2007;3:455–61.

    PubMed  PubMed Central  Google Scholar 

  58. Mulier JP. Perioperative opioids aggravate obstructive breathing in sleep apnea syndrome: mechanisms and alternative anesthesia strategies. Curr Opin Anaesthesiol. 2016;29:129–33.

    Article  CAS  PubMed  Google Scholar 

  59. Peppard PE, Young T, Barnet JH, Palta M, Hagen EW, Hla KM. Increased prevalence of sleep-disordered breathing in adults. Am J Epidemiol. 2013;177:1006–14.

    Article  PubMed  PubMed Central  Google Scholar 

  60. Webster LR, Choi Y, Desai H. Sleep-disordered breathing and chronic opioid therapy. Pain Med. 2008;9:425–32.

    Article  PubMed  Google Scholar 

  61. Mogri M, Desai H, Webster L, Grant BJ, Mador MJ. Hypoxemia in patients on chronic opiate therapy with and without sleep apnea. Sleep Breath. 2009;13:49–57.

    Article  PubMed  Google Scholar 

  62. Feng Y, He X, Yang Y, Chao D, Lazarus LH, Xia Y. Current research on opioid receptor function. Curr Drug Targets. 2012;13:230–46.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Xia Y, editor. Neural function of the delta-opioid receptor. Basel: Springer International Publishing; 2015.

    Google Scholar 

  64. Fareed A, Patil D, Scheinberg K, Blackinton Gale R, Vayalapalli S, Casarella J, et al. Comparison of QTc interval prolongation for patients in methadone versus buprenorphine maintenance treatment: a 5-year follow-up. J Addict Dis. 2013;32:244–51.

    Article  PubMed  Google Scholar 

  65. Fanoe S, Jensen GB, Sjogren P, Korsgaard MP, Grunnet M. Oxycodone is associated with dose-dependent QTc prolongation in patients and low-affinity binding of hERG activity in vitro. Br J Clin Pharmacol. 2009;67:172–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Ventura C, Spurgeon H, Lakatta EG, Guarnieri C, Capogrossi MC. Kappa and delta opioid receptor stimulation affects cardiac myocyte function and Ca2+ release from an intracellular pool in myocytes and neurons. Circ Res. 1992;70:66–81.

    Article  CAS  PubMed  Google Scholar 

  67. Fry CH, Henry J. The mode of action of several opioids on cardiac muscle. Exp Physiol. 1997;82:261–72.

    Article  PubMed  Google Scholar 

  68. Vuong C, Van Uum SHM, O’Dell LE, Lutfy K, Friedman TC. The effects of opioids and opioid analogs on animal and human endocrine systems. Endocr Rev. 2010;31:98–132.

    Article  CAS  PubMed  Google Scholar 

  69. Gudin JA, Laitman A, Nalamachu S. Opioid related endocrinopathy. Pain Med. 2015;16:S9–15.

    Article  PubMed  Google Scholar 

  70. De Maddalena C, Bellini M, Berra M. Opioid-induced hypogonadism: why and how to treat it. Pain Physician. 2012;15:ES111–8.

    PubMed  Google Scholar 

  71. Elliott JA, Horton E, Fibuch EE. The endocrine effects of long-term oral opioid therapy: a case report and review of the literature. J Opioid Manag. 2011;7:145–54.

    PubMed  Google Scholar 

  72. Rhodin A, Stridsberg M, Gordh T. Opioid endocrinopathy: a clinical problem in patients with chronic pain and long-term opioid treatment. Clin J Pain. 2010;26:374–80.

    Article  PubMed  Google Scholar 

  73. Gozashti MH, Mohammadzadeh E, Divsalar K, Shokoohi M. The effect of opium addiction on thyroid function tests. J Diabetes Metab Disorders. 2014;13:5–10.

    Article  Google Scholar 

  74. Al-Hashimi M, Scott SW, Thompson JP, Lambert DG. Opioids and immune modulation: more questions than answers. Br J Anaesth. 2013;111:80–8.

    Article  CAS  PubMed  Google Scholar 

  75. Pomorska DK, Gach K, Janecka A. Immunomodulatory effects of endogenous and synthetic peptides activating opioid receptors. Mini-Rev Med Chem. 2014;14:1148–55.

    Article  CAS  PubMed  Google Scholar 

  76. Boland JW, McWilliams K, Ahmedzai SH, Pockley AG. Effects of opioids on immunologic parameters that are relevant to anti-tumour immune potential in patients with cancer: a systematic literature review. Br J Cancer. 2014;111:866–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Hutchinson MR, Shavit Y, Grace PM, Rice KC, Maier SF, Watkins LR. Exploring the neuroimmunopharmacology of opioids: an integrative review of mechanisms of central immune signaling and their implications for opioid analgesia. Pharmacol Rev. 2011;63:772–810.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. Bodera P, Stankiewicz W, Kocik J. Interactions of orphanin FQ/nociceptin (OFQ/N) system with immune system factors and hypothalamic-pituitary-adrenal (HPA) axis. Pharmacol Rep. 2014;66:288–91.

    Article  CAS  PubMed  Google Scholar 

  79. Hall DM, Suo JL, Weber RJ. Opioid mediated effects on the immune system: sympathetic nervous system involvement. J Neuroimmunol. 1998;83:29–35.

    Article  CAS  PubMed  Google Scholar 

  80. Porreca F, Ossipov MH. Nausea and vomiting side effects with opioid analgesics during treatment of chronic pain: mechanisms, implications, and management options. Pain Med. 2009;10:654–62.

    Article  PubMed  Google Scholar 

  81. Poulsen JL, Brock C, Olesen AE, Nilsson M, Drewes AM. Evolving paradigms in the treatment of opioid-induced bowel dysfunction. Therap Advan Gastroenterol. 2015;8:360–72.

    Article  CAS  Google Scholar 

  82. Van Noord BA, Roffey P, Thangathurai D. Abdominal compartment syndrome following opioid-induced postoperative ileus. J Clin Anesth. 2013;25:146–9.

    Article  PubMed  Google Scholar 

  83. Cuppoletti J, Chakrabarti J, Tewari K, Malinowska DH. Methadone but not morphine inhibits lubiprostone-stimulated cl− currents in T84 intestinal cells and recombinant human ClC-2, but not CFTR cl− currents. Cell Biochem Biophys. 2013;66:53–63.

    Article  CAS  PubMed  Google Scholar 

  84. Thompson DR. Narcotic analgesic effects on the sphincter of Oddi: a review of the data and therapeutic implications in treating pancreatitis. Am J Gastroenterol. 2001;96:1266–72.

    Article  CAS  PubMed  Google Scholar 

  85. Verhamme KM, Sturkenboom MC, Stricker BH. Drug-induced urinary retention: incidence, management and prevention. Drug Saf. 2008;31:373–88.

    Article  CAS  PubMed  Google Scholar 

  86. Benyamin R, Trescot AM, Datta S, Buenaventura R, Adlaka R, Sehgal N, et al. Opioid complications and side effects. Pain Physician. 2008;11(2 Suppl):S105–20.

    PubMed  Google Scholar 

  87. Cherny N, Ripamonti C, Pereira J, Davis C, Fallon M, McQuay H, et al. Strategies to manage the adverse effects of oral morphine: an evidence-based report. J Clin Oncol. 2001;19:2542–54.

    Article  CAS  PubMed  Google Scholar 

  88. Kumar K, Singh SI. Neuraxial opioid-induced pruritus: an update. J Anaesthesiol Clin Pharmacol. 2013;29:303–7.

    Article  PubMed  PubMed Central  Google Scholar 

  89. Kalso E, Edwards J, Moore R, McQuay HJ. Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain. 2004;112:372–80.

    Article  CAS  PubMed  Google Scholar 

  90. Furlan AD, Sandoval JA, Mailis-Gagnon A, Tunks E. Opioids for chronic non—cancer pain: a meta—analysis of effectiveness and side effects. Can Med Assoc J. 2006;174:1589–94.

    Article  Google Scholar 

  91. Trescot AM, Glaser SE, Hansen H, Benyamin R, Patel S, Manchikanti L. Effectiveness of opioids in the treatment of chronic non-cancer pain. Pain Physician. 2008;11:S181–200.

    PubMed  Google Scholar 

  92. Papaleontiou M, Henderson CR, Turner BJ, Moore AA, Olkhovskaya Y, Amanfo L, et al. Outcomes associated with opioid use in the treatment of chronic non-cancer pain among older adults: a systematic review and meta-analysis. J Am Geriatr Soc. 2010;58:1353–69.

    Article  PubMed  PubMed Central  Google Scholar 

  93. Furlan A, Chaparro LE, Irvin E, Mailis-Gagnon A. A comparison between enriched and nonenriched enrollment randomized withdrawal trials of opioids for chronic noncancer pain. Pain Res Manag. 2011;16:337–51.

    Article  PubMed  PubMed Central  Google Scholar 

  94. McNicol ED, Midbari A, Eisenberg E. Opioids for neuropathic pain. Cochrane Reviews. 2013; doi:10.1002/14651858.CD006146.pub2.

  95. Reinecke H, Weber C, Lange K, Simon M, Stein C, Sorgatz H. Analgesic efficacy of opioids in chronic pain: recent meta-analysis. Br J Pharmacol. 2015;172:324–33.

    Article  CAS  PubMed  Google Scholar 

  96. Chou R, Turner JA, Devine EB, Hansen RN, Sullivan SD, Blazina I, et al. The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a national institutes of health pathways to prevention workshop. Ann Intern Med. 2015;162:276–86.

    Article  PubMed  Google Scholar 

  97. Dasgupta N, Funk MJ, Proescholdbell S, Hirsch A, Ribisl KM, Marshall S. Cohort study of the impact of high-dose opioid analgesics on overdose mortality. Pain Med. 2016;17:85–98.

    PubMed  Google Scholar 

  98. Dasgupta N, Funk MJ, Proescholdbell S, Hirsch A, Ribisl KM, Marshall S. Cohort study of the impact of high-dose opioid analgesics on overdose mortality. Pain Med. 2016;17(1):85–98.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Northern Anesthesia & Pain Medicine, LLC, Eagle River, Alaska, USA

    Heath B. McAnally MD, MSPH (Medical Director, Clinical Instructor)

  2. WWAMI Program, University of Washington School of Medicine, Anchorage, Alaska, USA

    Heath B. McAnally MD, MSPH (Medical Director, Clinical Instructor)

Authors
  1. Heath B. McAnally MD, MSPH
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG

About this chapter

Cite this chapter

McAnally, H.B. (2018). Understanding the Agent, Part II: Adverse Effects. In: Opioid Dependence . Springer, Cham. https://doi.org/10.1007/978-3-319-47497-7_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-47497-7_3

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-47496-0

  • Online ISBN: 978-3-319-47497-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation